Navigation Links
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Date:6/4/2009

SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced a strategic restructuring to focus its operations on the development of ANA598, in particular a proposed Phase II study in hepatitis C patients of ANA598 in combination with pegylated interferon-alpha and ribavirin.

As part of this restructuring, the Company intends to suspend further development of ANA773 and is reducing its workforce by approximately 40%. Pending the outcome and analysis of data from current cohorts in ongoing studies in hepatitis C and oncology, Anadys intends to manage the ANA773 programs as potential out-licensing opportunities.

"We have now completed three Phase I studies of ANA598 and we have seen potent antiviral activity, as well as good tolerability," said Steve Worland, Ph.D., President and CEO of Anadys. "As we complete preparations for the first Phase II study of ANA598 in combination with interferon and ribavirin, we have decided to focus our future investments on this important asset and to take these cost-sparing measures which we expect to ensure our ability to complete the Phase II study with our expected cash resources. The proposed Phase II study is expected to provide important data at the end of this year and in the first two quarters of 2010."

The Company anticipates the reduction in force to generate annual cash expense savings of between approximately $4.0 million and $5.0 million. The Company estimates that it will incur one-time cash charges of approximately $1.1 million in severance costs and $0.2 million in continuation of benefits and outplacement services. The Company will retain the clinical development infrastructure required to conduct the Phase II study of ANA598, key capabilities directed toward pharmaceutical development and next-generation non-n
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
(Date:5/23/2013)... 2013 VG Energy, an agricultural biotech ... Renewable Research to conduct field trials using LipidMax ... is a majority owned subsidiary of VG Life ... Energy,s exclusively licensed compound LipidMax selectively inhibits certain ... plants, possessing a wide variety of applications including ...
(Date:5/23/2013)... May 23, 2013 Z Trim Holdings, Inc. ... to a variety of industries, announced that Chef ... discussion at this year,s National Restaurant Association ("NRA") NRA ... behalf of the Research Chefs Association.  Chef Ryan spoke ... Good, the Bad and the Ugly," joining four other ...
(Date:5/23/2013)... 23, 2013 During the conduct ... to adhere to principles of good clinical practice ... speaker Dr. Jeremy Lim, Fellow, Clinical Development at ... ,     Understand the International Conference on Harmonization ... additional regulations for the conduction of clinical trials ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... UW-Madison researchers may be moving toward ... disease, using stem cells. Also, students ... Technology Business Plan Contest, and Madison ... program. Original air date: Saturday, April ...
... biotech industry started in the late 1970s with the first IPOs ... an industry more than 25 years old. , ,An interesting article ... 1 states unequivocally that most industry cycles run about 50 years ... middle of its 50-year cycle. A new industry of significance usually ...
... Research institutions should create oversight committees to guide ... a panel of experts, including two University of ... , ,"In the absence of federal guidelines broadly ... embryonic stem cells, the scientific community and its ...
Cached Biology Technology:Biotech industry reaches midpoint in 50-year maturation cycle 2Biotech industry reaches midpoint in 50-year maturation cycle 3Biotech industry reaches midpoint in 50-year maturation cycle 4Biotech industry reaches midpoint in 50-year maturation cycle 5
(Date:5/22/2013)... conclude that the 20 percent reduction in lung ... chest X-ray (CXR) screening previously reported in the ... centers in the United States. , Philadelphia, PAPhysicians ... about the benefits and risks of LDCT lung ... New England Journal of Medicine of the ...
(Date:5/22/2013)... together in a major new effort to educate the ... Earth,s people with clean water that looms ahead in ... article in the current edition of Chemical & ... Chemical Society (ACS), the world,s largest scientific society. , ... Jerald L. Schnoor, Ph.D., explain that shortages of reliable ...
(Date:5/22/2013)... human health effects from disposal of millions of ... to recommend stronger government policies to encourage recovery, ... That,s the conclusion of a new paper in ... . , Oladele A. Ogunseitan and colleagues point ... powering everything from smart phones to components in ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... known as "dry water," which resembles powdered sugar, could ... dioxide, the major greenhouse gas that contributes to global ... the American Chemical Society. The powder shows bright promise ... may, for instance, be a greener, more energy-efficient way ...
... Lockheed Martin (NYSE: LMT ) and ZyGEM Corp. ... has potential to transform how law enforcement, homeland security and ... The prototype, called Rap I.D .™, will be ... session on Rapid DNA. The day-long session is sponsored by ...
... SEATTLE Super-sized electromagnetic coils are helping explain how ... being considered for placement along America,s coastal waters and ... of Energy,s Pacific Northwest National Laboratory are examining whether ... during and after exposure to an electromagnetic field similar ...
Cached Biology News:Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3Magnetic attraction for fish, crabs? 2Magnetic attraction for fish, crabs? 3
... C-terminal end of the mouse retinoic acid receptor beta (RAR*). The ... RAR*. The sequence of PEP-005 is (amino to carboxy terminus): C ... - S - V - E - N - S - G ... - L - Q (The N-terminal cysteine has been added to ...
... potential applications for the use of small ... expression via the RNA interference (RNAi) pathway ... and molecular biology fields. siRNA for experimental ... chemically or enzymatically, and then transfected into ...
... automated hybridization system for the processing of ... hybridization and post hybridization washing of microarrays ... can process up to 12 slides at ... software, enabling the user to run all ...
... biological data hidden in your samples with eArray ... you to create your own microarray designs that ... own pace and receive delivery of your arrays ... a secure, online array creation application tool that ...
Biology Products: